# US 2012/0253047 A1 · Process for the preparation of (r)-pramipexole

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253047 A1
- Document ID: US20120253047A1
- Status: Published application
- Kind: A1
- Application number: 13/450,803
- Filed: 2012-04-19
- Published: 2012-10-04
- Earliest claimed: 2004-03-19
- Assignees: Dipharma S.p.A.
- Inventors: Pietro ALLEGRINI; Gabriele Razzetti; Vittorio Lucchini
- Web page: https://patentgrep.com/patent/US20120253047A1

## CPC

- C07D 277/82: Nitrogen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to a novel process for the preparation of (R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, or a salt thereof.

## Claims

### Claim 1

Process for the preparation of a compound of formula (I), in a solid state thereof, or a salt thereof, as the single (R) enantiomer,
comprising alkylating a compound of formula (II), as the single (R) enantiomer,
wherein Ra is a free or protected amino group, R3 is hydrogen or a R4—O—CO— group, wherein R4 is a straight or branched C1-C4 alkyl, to obtain a compound of formula (V)
wherein Ra and R3 are as defined above, and, if necessary, removing the primary amino-protecting group and/or the R4—O—CO— group from the secondary amino group, and/or, if the case, converting a compound of formula (I) into a salt thereof, and/or, if the case, converting a salt of a compound of formula (I) into the free compound,
characterized in that:
a) a compound of formula (II), as single (R) enantiomer, or a salt thereof,
wherein Ra is a protected amino group and R3 is as defined above, is prepared by rearrangement of a compound of formula (III), or a salt thereof, as single (R) enantiomer,
wherein R is a protected amino group; via formation of isocyanate, and subsequent addition of a nucleophilic solvent or subsequent quenching in water in the presence of an acid; or
b) a compound of formula (II), as single (R) enantiomer, or a salt thereof,
wherein Ra is a free amino group and R3 is hydrogen; is prepared by rearrangement of a compound of formula (III), or a salt thereof, as single (R) enantiomer, as defined above; via formation of isocyanate, and subsequent addition of water, to obtain a compound of formula (IV)
wherein R′ has the same meaning as R above, and subsequent hydrolysis.

### Claim 2 (depends on 1)

A process according to claim 1, variant a) wherein quenching in water in the presence of an acidic agent affords a compound of formula (II), as defined in claim 1, wherein R3 is hydrogen.

### Claim 3 (depends on 1)

A process according to claim 1, variant a), wherein the nucleophilic solvent is a C1-C4 alkanol, to obtain a compound of formula (II), as defined in claim 1, wherein R3 is a R4—O—CO— group, wherein R4 is as defined in claim 1.

### Claim 4 (depends on 1)

A process according to claim 1, variant a), wherein the rearrangement reaction is carried out according to Curtius in a nucleophilic solvent, via formation of a compound of formula of formula (IIIa)
in which Y is N3;
and of a compound of formula (IIId)
wherein R5 is a straight or branched C1-C4 alkyl group, without recovery of the intermediates.

### Claim 5 (depends on 1)

A process according to claim 1, wherein the rearrangement takes place via formation of a isocyanate of formula (IIIc)
in which R is a protected amino group, and subsequent addition of a nucleophilic solvent or subsequent quenching in water in the presence of an acidic agent.

### Claim 6 (depends on 1)

A process according to claim 1, wherein the compound of formula (I) is R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form.

### Claim 7 (depends on 1)

A process according to claim 1, wherein the compound of formula (I) is (R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form, characterized by an XRPD spectrum as shown in FIG. 1, wherein the most intense peaks fall at 9.66, 10.77, 11.10, 12.99, 14.55, 16.56, 17.19, 17.94, 18.72, 21.42, 21.84, 23.49, 24.21, 27.00 and 28.23±0.2° in 2q.

### Claim 8 (depends on 1)

A process according to claim 1, wherein a salt of a compound of formula (I) is (R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt in crystalline form.

### Claim 9 (depends on 1)

A process according to claim 1, wherein a salt of a compound of formula (I) is (R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form, characterised by an XRPD spectrum as shown in FIG. 2, wherein the most intense peaks fall at 6.48, 12.06, 12.93, 13.29, 13.92, 15.15, 16.95, 17.25, 17.91, 19.47, 21.36, 24.21, 24.75, 24.99, 25.59 and 28.44±0.2° in 2q; and an IR spectrum as shown in FIG. 3 showing the most intense peaks at 3411, 2945, 2742, 2440, 1651, 1627, 1432, 1362, 1218, 1070, 1042, 982, 760 e 714 cm−1.

### Claim 10 (depends on 9)

A process according to claim 9, wherein said salt of a compound of formula (I) has an enantiomeric purity of at least about 99.9%.

### Claim 11

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form.

### Claim 12

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form, characterized by an XRPD spectrum as shown in FIG. 1, wherein the most intense peaks fall at 9.66, 10.77, 11.10, 12.99, 14.55, 16.56, 17.19, 17.94, 18.72, 21.42, 21.84, 23.49, 24.21, 27.00 and 28.23±0.2° in 2q.

### Claim 13

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form.

### Claim 14

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form, characterised by an XRPD spectrum as shown in FIG. 2, wherein the most intense peaks fall at 6.48, 12.06, 12.93, 13.29, 13.92, 15.15, 16.95, 17.25, 17.91, 19.47, 21.36, 24.21, 24.75, 24.99, 25.59 and 28.44±0.2° in 2q; and an IR spectrum as shown in FIG. 3, showing the most intense peaks at 3411, 2945, 2742, 2440, 1651, 1627, 1432, 1362, 1218, 1070, 1042, 982, 760 e 714 cm−1.

### Claim 15 (depends on 13)

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form, as defined in claim 13, having a water content ranging between about 5 and about 7% w/w.

### Claim 16 (depends on 13)

(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form, as defined in claim 13, with an enantiomeric purity of at least about 99.9%.
